PP
Therapeutic Areas
Opthea Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Sozinibercept (OPT-302) | Wet Age-Related Macular Degeneration (Wet AMD) | Phase 3 |
Leadership Team at Opthea
DM
Dr. Megan Baldwin
Chief Executive Officer & Managing Director
MF
Mr. Fredrik Wiklund
Chief Financial Officer & Company Secretary
DC
Dr. Celia Fung
Vice President, Clinical Development
DP
Dr. Pravin Dugel
Consulting Medical Director
MJ
Mr. Jeremy Curnock Cook
Non-Executive Chairman
PD
Prof. David Calcott
Non-Executive Director
MC
Ms. Christine Chow
Non-Executive Director
DS
Dr. Sherryl Robertson
Non-Executive Director
DA
Dr. Andrew Nash
Chief Scientific Officer
PD
Prof. David Charteris
Scientific Advisory Board Member